Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a common cause of cancer mortality in Asia. Most patients
present with intermediate or advanced disease. Percutaneous ethanol injection,
radiofrequency ablation, and transcatheter arterial chemoembolization (TACE) are not
considered as a curative treatment and have achieved very limited success in eradicating
large HCC.
Two phase III trials were shown to be efficacious and well-tolerated in patients with
advanced HCC. Median overall survival was significantly 2 to 3 months longer in the
sorafenib group than that in the placebo. It is interesting to recognize the combined
therapeutic effect of TACE with sorafenib. The proposed study will make an important
contribution to understanding not only the safety and efficacy of sorafenib in addition to
TACE in patients diagnosed with unresectable HCC, but this will also be the first clinical
trial prospectively to compare the effectiveness of sorafenib combined with TACE with that
of TACE alone in the treatment of unresectable HCC
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Effectiveness of sorafenib combined with TACE
Measure:overall survival Measured from the date of TACE until the date of death or last visit
1 year
No
min-shan chen, M.D. Ph.D.
Principal Investigator
Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University
China: Ministry of Health
TACE-Sorafenib
NCT01833299
January 2010
December 2014
Name | Location |
---|